Abstract
Both osteoporosis and hypertension are major diseases in aging populations. This work was provided to investigate the possible effect of the nonselective beta adrenoceptor antagonist; carvedilol against postmenopausal osteoporosis in adult rats. Ovariectomized rats were gavaged with carvedilol (10 mg/kg) daily for 60 days. Serum levels of estradiol, calcium and osteoblastic markers (alkaline phosphatase and osteocalcin) were measured. The bone resorbing cytokines (TNF-α and IL-6) were also evaluated. The oxidative stress markers were determined via measuring the lipid peroxidation product and the anti-oxidant markers in the serum. The bones were prepared for histomorphometric study. In comparison to the ovariectomized rats, carvedilol caused significant attenuation of the bone loss, biomechanical fragility, bone resorbing cytokines and oxidative stress. Current evidence suggests that administration of carvedilol has a beneficial effect on the bone quality in OVX rats via its antioxidant effect and attenuation of the bone resorbing cytokines.
Keywords: Beta blocker, carvedilol, IL-6, osteoporosis, oxidative stress, TNF-α.
Current Drug Therapy
Title:The Potential Effect of Carvedilol Against Osteoporosis in Ovariectomized Rats
Volume: 8 Issue: 3
Author(s): Vivian Boshra and Gehan Abdel Hamid El Wakeel
Affiliation:
Keywords: Beta blocker, carvedilol, IL-6, osteoporosis, oxidative stress, TNF-α.
Abstract: Both osteoporosis and hypertension are major diseases in aging populations. This work was provided to investigate the possible effect of the nonselective beta adrenoceptor antagonist; carvedilol against postmenopausal osteoporosis in adult rats. Ovariectomized rats were gavaged with carvedilol (10 mg/kg) daily for 60 days. Serum levels of estradiol, calcium and osteoblastic markers (alkaline phosphatase and osteocalcin) were measured. The bone resorbing cytokines (TNF-α and IL-6) were also evaluated. The oxidative stress markers were determined via measuring the lipid peroxidation product and the anti-oxidant markers in the serum. The bones were prepared for histomorphometric study. In comparison to the ovariectomized rats, carvedilol caused significant attenuation of the bone loss, biomechanical fragility, bone resorbing cytokines and oxidative stress. Current evidence suggests that administration of carvedilol has a beneficial effect on the bone quality in OVX rats via its antioxidant effect and attenuation of the bone resorbing cytokines.
Export Options
About this article
Cite this article as:
Boshra Vivian and Hamid El Wakeel Abdel Gehan, The Potential Effect of Carvedilol Against Osteoporosis in Ovariectomized Rats, Current Drug Therapy 2013; 8 (3) . https://dx.doi.org/10.2174/15748855113086660010
DOI https://dx.doi.org/10.2174/15748855113086660010 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review of Current Treatment Strategies for Varicose Veins
Recent Patents on Cardiovascular Drug Discovery Altered Steroid Metabolism and Insulin Signaling in PCOS Endometria: Impact in Tissue Function
Current Pharmaceutical Design Recent Progress on Anti-Liver Fibrosis Candidates in Patents of Herbal Medicinal Products
Recent Patents on Food, Nutrition & Agriculture Endocrinological Aspects of Proteinuria and Podocytopathy in Diabetes: Role of the Aldosterone/Mineralocorticoid Receptor System
Current Diabetes Reviews Effects of an Outpatient Service Rehabilitation Programme in Patients Affected by Pulmonary Arterial Hypertension: An Observational Study
Cardiovascular & Hematological Disorders-Drug Targets Review of Clinic Trials: Agents Targeting c-Met
Reviews on Recent Clinical Trials Cardiovascular Effects of Glucagon-Like Peptide 1
Mini-Reviews in Medicinal Chemistry The Therapeutic Potential of Mesenchymal Stem Cells in the Treatment of Atherosclerosis
Current Stem Cell Research & Therapy Advanced Glycation End Products (AGEs) and Cardiovascular Disease (CVD) in Diabetes
Cardiovascular & Hematological Agents in Medicinal Chemistry Ligands of Diltiazem Binding Site: An Overview of Some Chemotypes
Mini-Reviews in Medicinal Chemistry Stress and the α7 Nicotinic Acetylcholine Receptor
Current Drug Targets Vascular Adenosine Receptors; Potential Clinical Applications
Current Vascular Pharmacology Is Bilirubin a Marker of Vascular Disease and/or Cancer and is it a Potential Therapeutic Target?
Current Pharmaceutical Design Inhibitors of Vascular Endothelial Growth Factor in Cancer
Cardiovascular & Hematological Agents in Medicinal Chemistry Strain Imaging Echocardiography: What Imaging Cardiologists Should Know
Current Cardiology Reviews Drug Discovery and Design for Complex Diseases through QSAR Computational Methods
Current Pharmaceutical Design Insulin Resistance and the Renin-Angiotensin-Aldosterone System in Metabolic Syndrome and Obesity-Related Hypertension
Current Hypertension Reviews Post-stroke Depression Therapy: Where are we now?
Current Neurovascular Research Technology for the Production and Utilization of Food Protein-Derived Antihypertensive Peptides: A Review
Recent Patents on Biotechnology MicroRNA-136 Promotes Vascular Muscle Cell Proliferation Through the ERK1/2 Pathway by Targeting PPP2R2A in Atherosclerosis
Current Vascular Pharmacology